Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes

Giorgio Gandaglia, Matteo Soligo, Antonino Battaglia, Tim Muilwijk, Daniele Robesti, Elio Mazzone, Francesco Barletta, Nicola Fossati, Marco Moschini, Marco Bandini, Steven Joniau, Robert Jeffrey Karnes, Francesco Montorsi, Alberto Briganti

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: A role for local therapies including radical prostatectomy (RP) in prostate cancer (PCa) patients with clinical lymphadenopathies has been proposed. However, no data are available to identify men who would benefit from RP in this setting. Objective: To identify predictors of clinical recurrence (CR) in surgically managed PCa patients with clinical lymphadenopathies. Design, setting, and participants: We identified 162 patients with lymphadenopathies treated with RP and lymph node dissection at three referral centers. Outcome measures and statistical analyses: CR was defined as the onset of metastases detected by conventional imaging. Kaplan-Maier analyses assessed time to CR after stratifying patients according to the site of lymphadenopathies and nodal burden. Regression tree analysis stratified patients into risk groups on the basis of their preoperative characteristics. Results and limitations: Overall, 80% of patients had lymphadenopathies in the pelvis alone and 20% in the retroperitoneum ± pelvis. The median size of positive nodes was 13 mm. A total of 84 patients (52%) received neoadjuvant androgen deprivation therapy and 127 (78%) had pathological lymph node invasion. The median follow-up for survivors was 64 mo. The 8-yr CR-free and CSM-free survival rates were 59% and 80%, respectively. Biopsy grade group and preoperative nodal burden should identify patients more likely to experience CR. While <10% of men with biopsy grade group 1–3 and two or fewer clinical lymphadenopathies developed CR, up to 60% of patients with biopsy grade group 4–5 and retroperitoneal node involvement ultimately experienced CR at 8 yr after RP. The discrimination of the regression tree was 76% according to the area under the receiver operating characteristic curve. Our study is limited by potential unmeasured confounders and the relatively small sample size. Conclusions: Surgery in a multimodal setting might play a role in PCa patients with biopsy grade group 1–3 and/or enlarged nodes in the pelvis. Conversely, grade group 4–5 PCa and lymphadenopathies in the retroperitoneum are associated with worse oncologic outcomes. Patient summary: Approximately half of prostate cancer patients with clinical lymphadenopathies treated with radical prostatectomy are free from metastases at 8-yr follow-up. Radical prostatectomy with or without systemic therapies might play a role in selected patients with biopsy grade group 1–3 disease and/or enlarged nodes in the pelvis. Conversely, a higher grade group and the presence of lymphadenopathies in the retroperitoneum should identify candidates for systemic therapies upfront. Not all prostate cancer patients with clinical lymphadenopathies are affected by systemic disease. Radical prostatectomy with or without systemic therapies might be associated with long-term clinical recurrence-free survival in selected patients with biopsy grade group 1–3 disease and/or enlarged nodes in the pelvis.

Original languageEnglish (US)
Pages (from-to)817-825
Number of pages9
JournalEuropean urology
Volume75
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Combined Modality Therapy
Prostatectomy
Prostatic Neoplasms
Recurrence
Pelvis
Biopsy
Lymphadenopathy
Play Therapy
Neoplasm Metastasis
Therapeutics
Lymph Node Excision
ROC Curve

Keywords

  • Lymph node dissection
  • Nodal metastases
  • Node-positive disease
  • Prostate cancer
  • Radical prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. / Gandaglia, Giorgio; Soligo, Matteo; Battaglia, Antonino; Muilwijk, Tim; Robesti, Daniele; Mazzone, Elio; Barletta, Francesco; Fossati, Nicola; Moschini, Marco; Bandini, Marco; Joniau, Steven; Karnes, Robert Jeffrey; Montorsi, Francesco; Briganti, Alberto.

In: European urology, Vol. 75, No. 5, 01.05.2019, p. 817-825.

Research output: Contribution to journalArticle

Gandaglia, G, Soligo, M, Battaglia, A, Muilwijk, T, Robesti, D, Mazzone, E, Barletta, F, Fossati, N, Moschini, M, Bandini, M, Joniau, S, Karnes, RJ, Montorsi, F & Briganti, A 2019, 'Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes', European urology, vol. 75, no. 5, pp. 817-825. https://doi.org/10.1016/j.eururo.2018.10.042
Gandaglia, Giorgio ; Soligo, Matteo ; Battaglia, Antonino ; Muilwijk, Tim ; Robesti, Daniele ; Mazzone, Elio ; Barletta, Francesco ; Fossati, Nicola ; Moschini, Marco ; Bandini, Marco ; Joniau, Steven ; Karnes, Robert Jeffrey ; Montorsi, Francesco ; Briganti, Alberto. / Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. In: European urology. 2019 ; Vol. 75, No. 5. pp. 817-825.
@article{e4ef452005de4acc92836e164cd69beb,
title = "Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes",
abstract = "Background: A role for local therapies including radical prostatectomy (RP) in prostate cancer (PCa) patients with clinical lymphadenopathies has been proposed. However, no data are available to identify men who would benefit from RP in this setting. Objective: To identify predictors of clinical recurrence (CR) in surgically managed PCa patients with clinical lymphadenopathies. Design, setting, and participants: We identified 162 patients with lymphadenopathies treated with RP and lymph node dissection at three referral centers. Outcome measures and statistical analyses: CR was defined as the onset of metastases detected by conventional imaging. Kaplan-Maier analyses assessed time to CR after stratifying patients according to the site of lymphadenopathies and nodal burden. Regression tree analysis stratified patients into risk groups on the basis of their preoperative characteristics. Results and limitations: Overall, 80{\%} of patients had lymphadenopathies in the pelvis alone and 20{\%} in the retroperitoneum ± pelvis. The median size of positive nodes was 13 mm. A total of 84 patients (52{\%}) received neoadjuvant androgen deprivation therapy and 127 (78{\%}) had pathological lymph node invasion. The median follow-up for survivors was 64 mo. The 8-yr CR-free and CSM-free survival rates were 59{\%} and 80{\%}, respectively. Biopsy grade group and preoperative nodal burden should identify patients more likely to experience CR. While <10{\%} of men with biopsy grade group 1–3 and two or fewer clinical lymphadenopathies developed CR, up to 60{\%} of patients with biopsy grade group 4–5 and retroperitoneal node involvement ultimately experienced CR at 8 yr after RP. The discrimination of the regression tree was 76{\%} according to the area under the receiver operating characteristic curve. Our study is limited by potential unmeasured confounders and the relatively small sample size. Conclusions: Surgery in a multimodal setting might play a role in PCa patients with biopsy grade group 1–3 and/or enlarged nodes in the pelvis. Conversely, grade group 4–5 PCa and lymphadenopathies in the retroperitoneum are associated with worse oncologic outcomes. Patient summary: Approximately half of prostate cancer patients with clinical lymphadenopathies treated with radical prostatectomy are free from metastases at 8-yr follow-up. Radical prostatectomy with or without systemic therapies might play a role in selected patients with biopsy grade group 1–3 disease and/or enlarged nodes in the pelvis. Conversely, a higher grade group and the presence of lymphadenopathies in the retroperitoneum should identify candidates for systemic therapies upfront. Not all prostate cancer patients with clinical lymphadenopathies are affected by systemic disease. Radical prostatectomy with or without systemic therapies might be associated with long-term clinical recurrence-free survival in selected patients with biopsy grade group 1–3 disease and/or enlarged nodes in the pelvis.",
keywords = "Lymph node dissection, Nodal metastases, Node-positive disease, Prostate cancer, Radical prostatectomy",
author = "Giorgio Gandaglia and Matteo Soligo and Antonino Battaglia and Tim Muilwijk and Daniele Robesti and Elio Mazzone and Francesco Barletta and Nicola Fossati and Marco Moschini and Marco Bandini and Steven Joniau and Karnes, {Robert Jeffrey} and Francesco Montorsi and Alberto Briganti",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.eururo.2018.10.042",
language = "English (US)",
volume = "75",
pages = "817--825",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes

AU - Gandaglia, Giorgio

AU - Soligo, Matteo

AU - Battaglia, Antonino

AU - Muilwijk, Tim

AU - Robesti, Daniele

AU - Mazzone, Elio

AU - Barletta, Francesco

AU - Fossati, Nicola

AU - Moschini, Marco

AU - Bandini, Marco

AU - Joniau, Steven

AU - Karnes, Robert Jeffrey

AU - Montorsi, Francesco

AU - Briganti, Alberto

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Background: A role for local therapies including radical prostatectomy (RP) in prostate cancer (PCa) patients with clinical lymphadenopathies has been proposed. However, no data are available to identify men who would benefit from RP in this setting. Objective: To identify predictors of clinical recurrence (CR) in surgically managed PCa patients with clinical lymphadenopathies. Design, setting, and participants: We identified 162 patients with lymphadenopathies treated with RP and lymph node dissection at three referral centers. Outcome measures and statistical analyses: CR was defined as the onset of metastases detected by conventional imaging. Kaplan-Maier analyses assessed time to CR after stratifying patients according to the site of lymphadenopathies and nodal burden. Regression tree analysis stratified patients into risk groups on the basis of their preoperative characteristics. Results and limitations: Overall, 80% of patients had lymphadenopathies in the pelvis alone and 20% in the retroperitoneum ± pelvis. The median size of positive nodes was 13 mm. A total of 84 patients (52%) received neoadjuvant androgen deprivation therapy and 127 (78%) had pathological lymph node invasion. The median follow-up for survivors was 64 mo. The 8-yr CR-free and CSM-free survival rates were 59% and 80%, respectively. Biopsy grade group and preoperative nodal burden should identify patients more likely to experience CR. While <10% of men with biopsy grade group 1–3 and two or fewer clinical lymphadenopathies developed CR, up to 60% of patients with biopsy grade group 4–5 and retroperitoneal node involvement ultimately experienced CR at 8 yr after RP. The discrimination of the regression tree was 76% according to the area under the receiver operating characteristic curve. Our study is limited by potential unmeasured confounders and the relatively small sample size. Conclusions: Surgery in a multimodal setting might play a role in PCa patients with biopsy grade group 1–3 and/or enlarged nodes in the pelvis. Conversely, grade group 4–5 PCa and lymphadenopathies in the retroperitoneum are associated with worse oncologic outcomes. Patient summary: Approximately half of prostate cancer patients with clinical lymphadenopathies treated with radical prostatectomy are free from metastases at 8-yr follow-up. Radical prostatectomy with or without systemic therapies might play a role in selected patients with biopsy grade group 1–3 disease and/or enlarged nodes in the pelvis. Conversely, a higher grade group and the presence of lymphadenopathies in the retroperitoneum should identify candidates for systemic therapies upfront. Not all prostate cancer patients with clinical lymphadenopathies are affected by systemic disease. Radical prostatectomy with or without systemic therapies might be associated with long-term clinical recurrence-free survival in selected patients with biopsy grade group 1–3 disease and/or enlarged nodes in the pelvis.

AB - Background: A role for local therapies including radical prostatectomy (RP) in prostate cancer (PCa) patients with clinical lymphadenopathies has been proposed. However, no data are available to identify men who would benefit from RP in this setting. Objective: To identify predictors of clinical recurrence (CR) in surgically managed PCa patients with clinical lymphadenopathies. Design, setting, and participants: We identified 162 patients with lymphadenopathies treated with RP and lymph node dissection at three referral centers. Outcome measures and statistical analyses: CR was defined as the onset of metastases detected by conventional imaging. Kaplan-Maier analyses assessed time to CR after stratifying patients according to the site of lymphadenopathies and nodal burden. Regression tree analysis stratified patients into risk groups on the basis of their preoperative characteristics. Results and limitations: Overall, 80% of patients had lymphadenopathies in the pelvis alone and 20% in the retroperitoneum ± pelvis. The median size of positive nodes was 13 mm. A total of 84 patients (52%) received neoadjuvant androgen deprivation therapy and 127 (78%) had pathological lymph node invasion. The median follow-up for survivors was 64 mo. The 8-yr CR-free and CSM-free survival rates were 59% and 80%, respectively. Biopsy grade group and preoperative nodal burden should identify patients more likely to experience CR. While <10% of men with biopsy grade group 1–3 and two or fewer clinical lymphadenopathies developed CR, up to 60% of patients with biopsy grade group 4–5 and retroperitoneal node involvement ultimately experienced CR at 8 yr after RP. The discrimination of the regression tree was 76% according to the area under the receiver operating characteristic curve. Our study is limited by potential unmeasured confounders and the relatively small sample size. Conclusions: Surgery in a multimodal setting might play a role in PCa patients with biopsy grade group 1–3 and/or enlarged nodes in the pelvis. Conversely, grade group 4–5 PCa and lymphadenopathies in the retroperitoneum are associated with worse oncologic outcomes. Patient summary: Approximately half of prostate cancer patients with clinical lymphadenopathies treated with radical prostatectomy are free from metastases at 8-yr follow-up. Radical prostatectomy with or without systemic therapies might play a role in selected patients with biopsy grade group 1–3 disease and/or enlarged nodes in the pelvis. Conversely, a higher grade group and the presence of lymphadenopathies in the retroperitoneum should identify candidates for systemic therapies upfront. Not all prostate cancer patients with clinical lymphadenopathies are affected by systemic disease. Radical prostatectomy with or without systemic therapies might be associated with long-term clinical recurrence-free survival in selected patients with biopsy grade group 1–3 disease and/or enlarged nodes in the pelvis.

KW - Lymph node dissection

KW - Nodal metastases

KW - Node-positive disease

KW - Prostate cancer

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=85063258323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063258323&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2018.10.042

DO - 10.1016/j.eururo.2018.10.042

M3 - Article

C2 - 30409676

AN - SCOPUS:85063258323

VL - 75

SP - 817

EP - 825

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -